帕博利珠单抗联合安罗替尼四线治疗EGFR基因敏感突变阳性肺腺癌1例  

Response of Lung Adenocarcinoma Harbouring Sensitizing EGFR Mutation to the Fourth-line Combination Treatment of Pembrolizumab and Anlotinib

作　　者：黄莉玲 秦燕[1] 赵凤仪 周生余[1] 石远凯[1] Liling HUANG;Yan QIN;Fengyi ZHAO;Shengyu ZHOU;Yuankai SHI(Department of Medical Oncology,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences&Peking Union Medical College,Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs,Beijing 100021,China)

机构地区：[1]国家癌症中心/国家肿瘤临床医学研究中心/中国医学科学院肿瘤医院内科/国家抗肿瘤药物临床研究北京市重点实验室,北京100021

出　　处：《中国肺癌杂志》2021年第10期739-742,共4页Chinese Journal of Lung Cancer

基　　金：重大新药创制科技重大专项基金(No.2017ZX09304015)资助。

摘　　要：中国晚期肺腺癌表皮生长因子受体(epidermal growth factor receptor,EGFR)基因敏感突变比例约为45.7%。EGFR基因敏感突变阳性的晚期非小细胞肺癌(non-small cell lung cancer,NSCLC)患者在EGFR-酪氨酸激酶抑制剂(tyrosine kinase inhibitor,TKI)治疗和化疗失败后治疗选择有限,寻找有效的治疗方案是临床的迫切需求。我们报道1例82岁的EGFR基因敏感突变阳性晚期肺腺癌女性患者,在奥希替尼、化疗及安罗替尼单药治疗均失败后,通过帕博利珠单抗和安罗替尼的联合治疗,截至2021年1月12日已获得超过21个月的无进展生存期,耐受性良好。45.7%of Chinese patients with advanced lung adenocarcinoma were reported to harbour sensitizing epidermal growth factor receptor(EGFR)mutations.Limited therapeutic options are left for non-small cell lung cancer(NSCLC)harbouring sensitizing EGFR mutations after failure of EGFR-tyrosine kinase inhibitor(TKI)therapy and chemotherapy,finding effective options for them is an unmet clinic need.Herein we reported a case that till January 12,2021,an 82-year-old female with sensitizing EGFR-mutant advanced lung adenocarcinoma received a surprising progression-free survival(PFS)benefit of over 21 months from the combination therapy of pembrolizumab and anlotinib after her failure of treatments of osimertinib,chemotherapy and anlotinib-monotherapy.

关 键 词：肺肿瘤 帕博利珠单抗 安罗替尼 免疫治疗 抗血管生成 

分 类 号：R734.2[医药卫生—肿瘤]